Prevention and treatment of osteoporosis in patients with inflammatory bowel disease

American Journal of Gastroenterology

Volumn 94, Issue 4, 1999, Pages 878-883

  Valentine, John F ^a   Sninsky, Charles A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; ETIDRONIC ACID;

BONE DENSITY; BONE MASS; CALCIUM ABSORPTION; CHRONIC INFLAMMATION; ENTERITIS; ENTEROPATHY; ESOPHAGUS ULCER; HUMAN; NUTRITIONAL DEFICIENCY; OSTEOPENIA; OSTEOPOROSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMALL INTESTINE RESECTION;

ANTI-INFLAMMATORY AGENTS; BONE DENSITY; CALCITONIN; CALCIUM CARBONATE; DIPHOSPHONATES; EXERCISE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; OSTEOPOROSIS; PREDNISONE; RISK FACTORS; VITAMIN D;

EID: 0033118711     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00036-2     Document Type: Review

References (40)

1. Compston JE. Review article: Osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmacol Ther 1995;9:237-50.
2. Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: A prospective study. Osteoporosis Int 1995;5:156-60.
3. Andreassen H, Rungby J, Dahlerup JF, et al. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997; 32:1247-55.
4. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28: 410-5.
5. Bjarnason J, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228-33.
6. Silverberg MS, Mikoalainis S, Steinhart AH. Low bone mineral density (BMD) in Crohn's disease (CD) occurs independent of corticosteroid use. Gastroenterol 1998;! 14:A1086 (abstract).
7. Barrett-Connor E. The economic and human cost of osteoporotic fracture. Am J Med 1995;98(suppl 2A):3S.
8. Riggs BL, Melton LJ. The prevention and treiftment of osteoporosis. N Engl J Med 1992;327:620-7.
9. Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fracture in postmenopausal osteoporosis. N Engl J Med 1995;333: 1437-43.
10. Hahn TJ. Metabolic bone disease. In: Kelly WN, Harris ED, Ruddy S, et al., eds. Textbook of rheumatology, 4th edition. Philadelphia: WB Saunders, 1993:1593-627.
11. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-801.
12. Peat ID, Heals S, Reid DM, et al. Steroid induced osteoporosis: An opportunity for prevention? Ann Rheum Dis 1995;54:66-8.
13. Walsh LJ, Won ÇA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. Br Med J 1996;313: 344-6.
14. Monologies SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305.
15. Bikle DD. Bone disease due to nutritional, gastrointestinal, and hepatic disorders. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992: 951-76.
16. Compston JE, Creamer B. Plasma levels and intestinal absorption of 25-hydroxy vitamin D' in patients with small intestinal resections. Gut 1977;18:171-5.
17. Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn's disease but not in patients -with ulcerative colitis: A population based study. Gut 1997; 40:313-9.
18. Pignot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992;37:1396-1403.
19. Miller PD, Bonnick SL, Rosen CJ, et al. Clinical utility of bone mass measurement in adults: consensus of an international panel. Semin Arthritis Rheum 1996;25:361-72.
20. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for the prediction of hip fractures. Lancet 1993; 341:72-5.
21. Joseph JC. Corticosteroid-induced osteoporosis. Am J Hosp Pharm 1994;51:188-97.
22. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss: A longitudinal study of alternate day therapy in patient with bronchial asthma using quantitative computer tomography. Eur J Clin Pharmacol 1983;25: 615-20.
23. Hodsman AB, Toogood JH, Jennings B, et al. Differential effect of inhaled budesonide and oral prednisolone on serum osteocalcin. J Clin Endocrinol Metab 1991;72:530-40.
24. Lo-Cascio V, Bonucci E, Imbimbo B, et al. Bone loss after glucocorticoid therapy. Calcif Tiss Int 1984;36:435-8.
25. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996;125:961-8.
26. Gluck GK, Murphy WA, Hahn TJ, et al. Bone loss in adults receiving alternate day glucocorticoid therapy: A comparison with daily therapy. Arthritis Rheum 1981;24: 892-8.
27. Melton LJ, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227-33.
28. Weiss NS, Ure B, Ballard JH, et al. Decreased risk of fracture of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-8.
29. Clements D, Compston JE, Evans WD, et al. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993;34:1543-6.
30. Adachi JD, Bensen WG, Blanchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced 'osteoporosis: A 3 year follow up. J Rheumatol 1996;23:9951000.
31. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol and calcitonin. N Engl J Med 1993;328:1747-52.
32. Rosen HN, Dresner-Pollak R, Moses AC, et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue .Int 1994;54:26-9.
33. Chestnut CH, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:2937.
34. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
35. Poubelle PE, Adaehi J, Hawkins F, et al. Alendronate increases bone mineral density in patients on glucocorticoid therapy: Results of the multinational study. Arthritis Rheum 1997;9:S327 (abstract).
36. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
37. Adams' JS, Wahl TO, Lukert BP. Effects of hydrochloro-thiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 1981;30:217-21.
38. Aubin R, Menard P, Lajeunesse D. Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int 1996;50:1476-82.
39. Falcini F, Trapani S, Ermini M, et al. Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif Tissue Int 1996;58:166-9.
40. Maconi G, Bianchi Porro G. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995;90:1889-90.